Availability of the Q2 2025 Aide mémoire

As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on July 31, 2025. 

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Relations médias
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]
Evan Berland | + 1 215 432 0234 | [email protected]
Léa Ubaldi | + 33 6 30 19 66 46 | [email protected]
Léo Le Bourhis | + 33 6 75 06 43 81 | [email protected]
Victor Rouault | + 33 6 70 93 71 40 | [email protected]
Timothy Gilbert | + 1 516 521 2929 | [email protected]

Relations investisseurs
Thomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]
Alizé Kaisserian | + 33 6 47 04 12 11 | [email protected]
Felix Lauscher | + 1 908 612 7239 | [email protected]
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | + 33 7 85 93 30 17 | [email protected]
Tarik Elgoutni | + 1 617 710 3587 | [email protected]
Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected]
Yun Li | + 33 6 84 00 90 72 | [email protected]